KineMed, Bristol-Myers Squibb Extend Collaboration Covering Alzheimer's Disease | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KineMed today said that it and Bristol-Myers Squibb have extended a collaboration covering Alzheimer's disease and other neurodegenerative ailments.

Under the extension, KineMed is granting Bristol-Myers Squibb a non-exclusive license to KineMed's technology for the identification and characterization of AD biomarkers in cerebrospinal fluid.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.